Glycogen Synthase Kinase 3 (GSK3) is one of the Serine/Threonine protein kinases, which
has gained a lot of attention for its role in a variety of pathways. It has two isoforms, GSK3α and
GSK3β. However, GSK3β is highly expressed in different areas of the brain and has been implicated
in Alzheimer’s disease as it is involved in tau phosphorylation. Due to its high specificity concerning
substrate recognition, GSK3 has been considered as an important target. In the last decade, several
GSK3 inhibitors have been reported and two molecules are in clinical trials. This review collates the
information published in the last decade about the role of GSK3 in Alzheimer’s disease and progress in
the development of its inhibitors. Using this collated information, medicinal chemists can strategize
and design novel GSK3 inhibitors that could be useful in the treatment of Alzheimer’s disease.
Keywords: Glycogen Synthase Kinase 3, Alzheimer`s disease, Cancer, Inflammation, Inhibitors, Tideglusib.
Rights & PermissionsPrintExport